

Sun Pharmaceutical Industries Ltd.
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



FOR IMMEDIATE RELEASE

Sun Pharma Launches SEZABY™ (phenobarbital sodium) in the U.S. for Treatment of Neonatal Seizures

- *First and only FDA-approved product for treating seizures in neonatal patients*

Mumbai, India and Princeton, N.J., January 25, 2023 – Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced the launch of SEZABY™ (phenobarbital sodium) in the U.S. for the treatment of neonatal seizures. SEZABY is the first and only product approved by the U.S. Food and Drug Administration (US FDA) for the treatment of neonatal seizures in term and preterm infants.

SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection. It was granted orphan drug designation by the US FDA for the treatment of neonatal seizures.

"The launch of SEZABY is an exciting addition to our growing portfolio of specialty branded products in the U.S.," said Abhay Gandhi, CEO North America, Sun Pharma. "As the first and only FDA-approved product for the treatment of seizures in term and preterm infants, SEZABY has the potential to make a meaningful difference in the lives of patients and their families, and we are proud to be able to provide physicians with this new treatment option."

About Neonatal Seizures

Seizures are more common in the neonatal period (first 28 days of life) than at any other time during life. The incidence of seizures during the first month of life is approximately 1 to 4 per thousand babies.¹ Their occurrence is associated with poor outcomes such as cerebral palsy, global developmental delay, and epilepsy in up to 40 to 60% of babies who suffer seizures.²

About SEZABY (phenobarbital sodium)

SEZABY is a benzyl alcohol-free and propylene glycol-free formulation of phenobarbital sodium powder for injection. It was granted orphan drug designation by the US FDA for the treatment of neonatal seizures.

SEZABY was approved based on the results of NEOLEV2, a phase 2 study that evaluated levetiracetam compared to phenobarbital in the first-line treatment of neonatal seizures. The randomized controlled trial compared the incidence of recurrent seizures in neonates treated with phenobarbital vs. levetiracetam in 94 neonates. Twenty-four hours following the administration of phenobarbital or levetiracetam, 73% vs. 25% were seizure-free in the respective groups.

Registered Office : SPARC, Tandalja, Vadodara – 390 012. India

Sun Pharmaceutical Industries Ltd.
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



The most common adverse reactions (incidence > 5% patients overall) were abnormal respiration, sedation, feeding disorder, and hypotension.

SEZABY for injection is supplied as a sterile white to off-white, lyophilized powder in single-dose clear glass vials containing 100 mg of phenobarbital sodium.

Important Safety Information

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; DEPENDENCE AND WITHDRAWAL REACTIONS AFTER USE OF SEZABY FOR A LONGER DURATION THAN RECOMMENDED; and ABUSE, MISUSE, AND ADDICTION WITH UNAPPROVED USE IN ADOLESCENTS AND ADULTS

- **Concomitant use of phenobarbital products, including SEZABY, and opioids may result in profound sedation, respiratory depression, coma, and death. If a decision is made to use concomitantly, limit dosages and durations to the minimum required, and monitor patients for respiratory depression and sedation.**
- **Although SEZABY is indicated only for short-term use, if used for a longer duration than recommended, abrupt discontinuation or rapid dosage reduction may precipitate acute withdrawal reactions, which can be life-threatening. For patients receiving SEZABY for a longer duration than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue SEZABY.**
- **SEZABY is not approved for use in adolescents or adults. The unapproved use of SEZABY in adolescents and adults exposes them to risks of abuse, misuse, and addiction, which can lead to overdose or death.**

Please see [full Prescribing Information](#), including Boxed WARNING, for SEZABY.

Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

Registered Office : SPARC, Tandalja, Vadodara – 390 012. India

Sun Pharmaceutical Industries Ltd.
SUN HOUSE, CTS No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai 400063, India
Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343
CIN: L24230GJ1993PLC019050
www.sunpharma.com



References:

1. Vasudevan C, Levene M. Epidemiology and aetiology of neonatal seizures. Semin Fetal Neonatal Med. 2013 Aug;18(4):185-91
2. Uria-Avellanal C, Marlow N, Rennie JM. Outcome following neonatal seizures Semin Fetal Neonatal Med 2013 Aug;18(4):224-32

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across six continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com and follow us on Twitter @SunPharma_Live.

Contacts:

Investors:

Dr. Abhishek Sharma
Tel +91 22 4324 4324, Xtn 2929
Tel Direct +91 22 4324 2929
Mobile +91 98196 86016
E mail abhi.sharma@sunpharma.com

Media:

Gaurav Chugh
Tel +91 22 4324 4324, Xtn 5373
Tel Direct +91 22 4324 5373
Mobile +91 98104 71414
E mail gaurav.chugh@sunpharma.com

US Contacts:

Media:
Janet Metz
Mobile 609-389-3044
E mail janet.metz@sunpharma.com

Registered Office : SPARC, Tandalja, Vadodara – 390 012. India